8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,235 shares of the biotechnology company’s stock, valued at approximately $191,000.

Several other large investors also recently bought and sold shares of the company. Nordea Investment Management AB purchased a new position in Arcturus Therapeutics in the first quarter valued at about $1,846,000. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock valued at $38,061,000 after buying an additional 286,546 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Arcturus Therapeutics during the second quarter worth approximately $596,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Arcturus Therapeutics by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock worth $1,078,000 after buying an additional 778 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Arcturus Therapeutics in the second quarter valued at $718,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Insider Activity

In related news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Stock Up 1.1 %

Shares of NASDAQ ARCT opened at $20.00 on Thursday. The stock has a market capitalization of $538.64 million, a P/E ratio of -5.12 and a beta of 2.61. The firm’s 50-day moving average price is $21.21 and its two-hundred day moving average price is $25.13. Arcturus Therapeutics Holdings Inc. has a 52-week low of $17.52 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter last year, the business posted ($1.98) EPS. As a group, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Leerink Partners assumed coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target for the company. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.